We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CDR-Life Inc., a biotherapeutics company developing tumor-specific immunotherapies based on a proprietary antibody platform, today announced the expansion of its leadership team with the appointment of Björn Peters as chief business officer.
Boehringer Ingelheim has signed a collaboration and licensing agreement with CDR-Life for the research and development of antibody fragment-based therapeutics to treat geographic atrophy (GA).